
CLAIMS

1. A compound of general formula (I) including all tautomeric forms, all enantiomers, isotopic variants, and salts and solvates thereof:



(I)

wherein:

R^1 is selected from methyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, ethynyl and CN; or

R^2 is selected from methyl and CH_2OH;

R^3 is selected from H and methyl; or

R^2 and R^3 together with the carbon atom to which they are attached form a 3- to 10-membered carbocyclic or oxygen-containing heterocyclic ring system, either of which is optionally substituted, in addition to the R^1 group, with one or more substituents selected from OH, halo, C_{1-4} alkyl, C_{1-4} alkyl substituted with one or more OH substituents, and C_{1-4} haloalkyl; or

when R^2 and R^3 together with the carbon atom to which they are attached form a 4- to 6-membered carbocyclic ring substituted, in addition to the R^1 group, with OH, halo, methyl or CH_2OH, R^1 may also be H; or

when R^2 and R^3 together with the carbon atom to which they are attached form a 4- to 6-membered carbocyclic ring, which is unsubstituted apart from the R^1 group; R^1 may also be CH_2OH; or

R^1, R^2 and R^3 together with the carbon atom to which they are attached combine to form

a 5- to 8-membered bridged carbocyclic or heterocyclic ring system optionally substituted with one or more substituents selected from OH, halo, C_{1-4} alkyl and C_{1-4} haloalkyl;

R^4 is H or halo;

each of R^5 and R^7 is independently selected from H, halo, C_{1-3} alkyl and C_{1-3} haloalkyl;

R^6 is selected from halo, CN and C_{1-4} alkyl optionally substituted with one or more substituents selected from halo and OH;

R^8 is methyl or ethyl, either of which is optionally substituted with one or more halogen substituents;

R^9 is OH, CH_2OH or methyl or ethyl, either of which is optionally substituted with one or more halogen substituents; or

R^8 and R^9 together with the carbon atom to which they are attached form either a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring optionally substituted, in addition to the R^{10} group, with one or more substituents selected from OH, F and CH_2OH; or an ethenyl group optionally substituted with one or two halogen substituents;

R^{10} is selected from H, CN, OH, cycloalkyl optionally substituted with OH, and C_{1-4} alkyl optionally substituted with one or more substituents selected from halo, OH and a 3- to 6-membered cycloalkyl or heterocyclic group, either of which is optionally substituted with OH; or

R^8, R^9 and R^{10} together with the carbon atom to which they are attached form a 5- to 8-membered fused or bridged carbocyclic ring system optionally substituted with one or more substituents selected from OH, F and CH_2OH;

provided that:

i. when R^5 and R^7 are H and R^6 is H or F, R^1, R^2, R^3, R^8, R^9 and R^{10} are not all methyl; and

ii. when R^2, R^3, R^8, R^9 and R^{10} are all methyl, R^5, R^6 and R^7 are not all H; and

iii. when R^1 is CN and R^2 and R^3 together with the carbon atom to which they are

attached form a 3- to 10-membered oxygen-containing heterocyclic ring, R^8, R^9 and R^{10} are not all methyl; and

iv. R^9 and R^{10} are not both OH.

2. A compound according to claim 1 wherein either:

R^8 and R^9 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring substituted, in addition to the R^{10} group, with one or more CH_2OH substituents and optionally with one or more further substituents selected from OH and F; or

R^8 and R^9 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring optionally substituted, in addition to the R^{10} group, with one or more substituents selected from OH and F; and R^{10} is CN or C_{1-4} alkyl substituted with one or more substituents selected from OH, a 3- to 6-membered cycloalkyl group optionally substituted with OH and a 3- to 6-membered heterocyclic group optionally substituted with OH; or

R^8 and R^9 together with the carbon atom to which they are attached form an ethenyl group optionally substituted with one or two halogen substituents; or

R^8, R^9 and R^{10} together with the carbon atom to which they are attached form a 5- to 8-membered fused or bridged carbocyclic ring system substituted with one or more CH_2OH substituents and optionally with one or more further substituents selected from OH and F.

3. A compound according to claim 2 wherein either:

R^8 and R^9 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring system which is unsubstituted except for the R^{10} group; and R^{10} is selected from CN and CH_2OH; or

R^8, R^9 and R^{10} together with the carbon atom to which they are attached form a 5- to 8-membered fused or bridged carbocyclic ring system substituted with CH_2OH.

4. A compound according to claim 1 wherein:

R^8 is methyl or ethyl, either of which is optionally substituted with one or more halogen substituents; and

R^9 is OH, CH_2OH or methyl or ethyl, either of which is optionally substituted with one or more halogen substituents; or

R^8 and R^9 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring optionally substituted, in addition to the R^{10} group, with one or more substituents selected from OH and F, and R^{10} is H, OH or C_{1-4} alkyl optionally substituted with one or more halo substituents; or

R^8, R^9 and R^{10} together with the carbon atom to which they are attached form a 5- to 8-membered fused or bridged carbocyclic ring system optionally substituted with one or more substituents selected from OH and F.

5. A compound according to claim 4 wherein:

R^8 is methyl or ethyl, R^9 is OH or CH_2OH and R^{10} is methyl or ethyl;

R^8 is methyl or ethyl, R^9 is methyl or ethyl and R^{10} is OH or C_{1-4} alkyl substituted with OH; or

R^8, R^9 and R^{10} are all methyl.

6. A compound according to any one of claims 1 to 5 wherein R^1 is methyl, difluoromethyl, trifluoromethyl, ethynyl or CN.

7. A compound according to any one of claims 1 to 6 wherein either:

R^2 is methyl and/or R^3 is H or methyl; or

R^2 and R^3 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring system, optionally substituted, in addition to R^1, with one or more substituents selected from OH, halo, C_{1-4} alkyl and C_{1-4} haloalkyl; or

R^1 is H and R^2 and R^3 together with the carbon atom to which they are attached form a 4- to 6-membered carbocyclic ring substituted with OH; or

R^1 is trifluoromethyl; and R^2 and R^3 together with the carbon atom to which they are attached form a cyclopropyl ring which is unsubstituted except for R^1.

8. A compound according to any one of claims 1 to 7 wherein:

R^4 is H; and/or
each of R^5 and R^7 is H; and/or
R^6 is halo, CN, CH_3, CF_3, CHF_2, CH_2F or CH_2OH.

9. A compound according to any one of claims 1 to 8 wherein R^8 is methyl or ethyl, especially methyl; and R^9 is methyl, CH_2OH or OH; or
R^8 and R^9 are each independently methyl or ethyl; or

R^8 and R^9 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring, wherein the ring is unsubstituted except for the R^{10} moiety and is selected from cycloalkyl rings and heterocyclic rings having a single ring oxygen atom.

10. A compound according to any one of claims 1 or 4 to 9, wherein R^{10} is selected from CN, cyclopropyl, cyclobutyl, unsubstituted methyl or methyl substituted with one or more substituents selected from fluoro, OH and a 3- to 6-membered cycloalkyl or heterocyclyl group.

11. A compound according to any one of claims 1 to 10 wherein R^8 and R^9 together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl or oxetanyl ring, which is either unsubstituted except for the R^{10} group or has a single CH_2OH substituent in addition to the R^{10} group; and R^{10} is methyl, CH_2OH, trifluoromethyl or cyano.

12. A compound according to any one of claims 1 to 11 wherein R^8, R^9 and R^{10} together with the carbon atom to which they are attached form a bridged ring system such as bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane or bicyclo[2.2.1]heptane, wherein the ring is unsubstituted or is substituted with a single CH_2OH substituent.

13. A compound according to claim 1 selected from:
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclopropyl)pyridine-2-carboxamide (Compound 1);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 1.1);

4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-ethynylcyclopentyl)pyridine-2-carboxamide (Compound 1.2);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanoethyl)pyridine-2-carboxamide (Compound 1.3);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyanoethyl]pyridine-2-carboxamide (Compound 1.3a/b);
4-[[2-(4-*tert*-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyanoethyl]pyridine-2-carboxamide (Compound 1.3 a/b);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 1.4);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 1.5);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-2-hydroxy-1-methyl-ethyl)pyridine-2-carboxamide (Compound 1.6);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide (Compound 1.6 a/b);
4-[[2-(4-*tert*-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide (Compound 1.6 a/b);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 1.7);
4-[[2-[2-Fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2);
N-(1-Cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 2.1);
N-*tert*-Butyl-4-[[2-[4-(1-cyano-1-methyl-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 2.2);
4-[[2-[4-(1-Cyano-1-methyl-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.3);
N-*tert*-Butyl-4-[[2-[4-(1-cyanocyclopropyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 2.4);
N-(1-Cyano-1-methyl-ethyl)-4-[[2-[4-(1,1-dimethyl-2-morpholino-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 2.5);
4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.6);
N-(1-Cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2,2,2-trifluoro-1-hydroxy-1-

methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 2.7);
4-[[2-[4-(1-Cyclopropyl-1-hydroxy-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.8);
4-[[2-[4-(4-Cyanotetrahydropyran-4-yl)-2-fluoro-5-hydroxy-phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.9);
4-[[2-[2-Fluoro-5-hydroxy-4-[2-(trifluoromethyl)oxetan-2-yl]phenyl] acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.10);
4-[[2-[2-Fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-propyl)phenyl] acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.11);
4-[[2-[2-Fluoro-5-hydroxy-4-[(1S)-1-hydroxy-1-methyl-propyl]phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.11 a/b);
4-[[2-[2-fluoro-5-hydroxy-4-[(1R)-1-hydroxy-1-methyl-propyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl] pyridine-2-carboxamide (Compound 2.11 a/b);
4-[[2-[5-Hydroxy-4-(1-hydroxy-1-methyl-ethyl)-2-methyl-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.12);
4-[[2-[2-Fluoro-5-hydroxy-4-[1-(hydroxymethyl)cyclobutyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.13);
N-(1-Cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-[2-(trifluoromethyl)oxetan-2-yl]phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 2.14);
4-[[2-[2-Fluoro-5-hydroxy-4-[4-(hydroxymethyl)tetrahydropyran-4-yl]phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.15);
4-[[2-[2-Fluoro-5-hydroxy-4-[1-(hydroxymethyl)cyclopropyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.16);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)-5-fluoro-pyridine-2-carboxamide (Compound 3);
N-(1-Cyanocyclopropyl)-4-[[2-[2-deuterio-6-fluoro-3-hydroxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl)ethyl]phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 4);
N-(1-Cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(1-methylcyclo butyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 5);
N-*tert*-Butyl-4-[[2-(4-*tert*-butyl-5-hydroxy-2-isopropyl-phenyl)acetyl]amino] pyridine-2-carboxamide (Compound 6);
N-*tert*-Butyl-4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl] acetyl]amino]pyridine-2-carboxamide (Compound 7);
4-[[2-(2-Fluoro-5-hydroxy-4-isopropenyl-phenyl)acetyl]amino]-N-[1-(trifluoromethyl) cyclopropyl]pyridine-2-carboxamide (Compound 7.1);

N-*tert*-Butyl-4-[[2-[2-fluoro-5-hydroxy-4-(1-methylcyclopropyl)phenyl] acetyl]amino]pyridine-2-carboxamide (Compound 8);
N-(1-Cyanocyclopropyl)-4-[[2-[2-fluoro-5-hydroxy-4-[1-(trifluoromethyl) cyclopropyl]phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 9);
4-[[2-(4-*tert*-Butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 10);
4-[[2-(4-*tert*-Butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-[1-(trifluoromethyl) cyclopropyl]pyridine-2-carboxamide (Compound 10.1);
4-[[2-(4-*tert*-Butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl) pyridine-2-carboxamide (Compound 10.2);
4-[[2-[2-Fluoro-5-hydroxy-4-(3-hydroxy-1,1-dimethyl-propyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 11);
N-(4-Cyanotetrahydropyran-4-yl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 12);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[3-(trifluoromethyl)oxetan-3-yl]pyridine-2-carboxamide (Compound 12.1);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[(1S,2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 12.2);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(2-hydroxy-1,1-dimethyl-ethyl)pyridine-2-carboxamide (Compound 12.3);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(hydroxymethyl)cyclobutyl]pyridine-2-carboxamide (Compound 12.4);
4-[[2-[2-Fluoro-5-hydroxy-4-(4-hydroxytetrahydropyran-4-yl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 13);
4-[[2-[2-Chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 14);
4-[[2-[5-Hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)-2-methyl-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 14.1);
N-(3,3-Difluoro-1-methyl-cyclobutyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 15);
4-[[2-[2-Chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 15.1);
4-[[2-[2-Chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(3,3-difluoro-1-methyl-cyclobutyl)pyridine-2-carboxamide (Compound 15.2);
4-[[2-[2-Chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-

(difluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 15.3);
N-[1-(Difluoromethyl)cyclopropyl]-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 15.4);
N-(1,1-Dimethylprop-2-ynyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 16);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 16.1);
N-(1-Cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 16.2);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 16.3);
4-[[2-[2,6-Difluoro-3-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 16.4);
4-[[2-[2-Fluoro-5-hydroxy-4-[2,2,2-trifluoro-1-(hydroxymethyl)ethyl]phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 17);
4-[[2-[2-Chloro-6-fluoro-3-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 18);
4-[[2-[2-Chloro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 19);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 20);
4-[[2-[2-Fluoro-5-hydroxy-4-[(1S)-2-hydroxy-1-methyl-ethyl]phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 20a/b);
4-[[2-[2-fluoro-5-hydroxy-4-[(1R)-2-hydroxy-1-methyl-ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl] pyridine-2-carboxamide (Compound 20a/b);
and salts and solvates of the above.

14. The compound of claim 13, which is 4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 1.5); or a salt or solvate thereof.

15. The compound of claim 14, which is N-(1-Cyanocyclopropyl)-4-[[2-[2-deuterio-6-fluoro-3-hydroxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl) ethyl]phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 4); or a salt or solvate thereof.

16. The compound of claim 13, which is 4-[[2-[2-Fluoro-5-hydroxy-4-[2,2,2-trifluoro-1-(hydroxymethyl)ethyl]phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 17); or a salt or solvate thereof.

17. The compound of claim 13, which is 4-[[2-(4-*tert*-Butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-[1-(trifluoromethyl) cyclopropyl]pyridine-2-carboxamide (Compound 10.1); or a salt or solvate thereof.

18. A compound according to any one of claims 1 to 17 for use in the treatment or prophylaxis of diseases and conditions affected by modulation of TMEM16A.

19. The use of a compound according to any one of claims 1 to 17 in the manufacture of a medicament for the treatment or prophylaxis of diseases and conditions affected by modulation of TMEM16A.

~~20. A method for the treatment or prophylaxis of diseases and conditions affected by modulation of TMEM16A, the method comprising administering to a patient in need of such treatment an effective amount of a compound according to any one of claims 1 to 17.~~

~~21~~20. A compound for use or~~,~~ a use ~~or a method~~ according to ~~any one of~~ claim~~s~~ 18 ~~to~~or ~~20~~19, wherein the diseases and conditions affected by modulation of TMEM16A are selected from respiratory diseases and conditions, dry mouth (xerostomia), intestinal hypermobility, cholestasis and ocular conditions.

~~22~~21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 17 and a pharmaceutically acceptable excipient.